Polymer conjugates with anticancer activity

Polymer conjugates may possess anticancer activity through a variety of mechanisms. The macro-molecules themselves may have anticancer activities, or, more typically, inert biocompatible polymers serve as carriers for low molecular weight anticancer agents. Polymer conjugates may also be targeted to increase the concentration of conjugate in the vicinity of a specific subset of cells. This article reviews the recent literature that pertains to polymer conjugates with anticancer activity. The types of polymers chosen as drug carriers and the biodistribution of polymers in the body are discussed. Also, the synthesis, biological properties, and the means used to evaluate the anticancer activities of polymer conjugates are detailed.

[1]  H. Jatzkewitz.  [Incorporation of physiologically-active substances into a colloidal blood plasma substitute. I. Incorporation of mescaline peptide into polyvinylpyrrolidone]. , 1954, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[2]  E. J. Ambrose,et al.  Specific Reactions of Polyelectrolytes with the Surfaces of Normal and Tumour Cells , 1958, British Journal of Cancer.

[3]  O. Wichterle,et al.  Hydrophilic Gels for Biological Use , 1960, Nature.

[4]  T. Slater,et al.  STUDIES ON SUCCINATE-TETRAZOLIUM REDUCTASE SYSTEMS. III. POINTS OF COUPLING OF FOUR DIFFERENT TETRAZOLIUM SALTS. , 1963, Biochimica et biophysica acta.

[5]  N. Mantel,et al.  Experimental screening procedures and clinical predictability value. , 1966, Cancer chemotherapy reports.

[6]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[7]  I. Sternlieb,et al.  Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. , 1968, The Journal of biological chemistry.

[8]  A. Morell,et al.  Physical and chemical studies on ceruloplasmin. IX. The role of galactosyl residues in the clearance of ceruloplasmin from the circulation. , 1970, The Journal of biological chemistry.

[9]  L Sprincl,et al.  Biological tolerance of poly(N-substituted methacrylamides). , 1971, Journal of biomedical materials research.

[10]  J. Kopeček,et al.  New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood. , 1973, Journal of biomedical materials research.

[11]  J. Kopeček,et al.  Poly[N-(2-hydroxypropyl)methacrylamide]—I. Radical polymerization and copolymerization , 1973 .

[12]  L Sprincl,et al.  Biological tolerance of ionogenic hydrophilic gels. , 1973, Journal of biomedical materials research.

[13]  D. Blow.  Stereochemistry of Substrate Binding and Hydrolysis in the Trypsin Family of Enzymes , 1974 .

[14]  J. Kopeček,et al.  Poly[N-(2-hydroxypropyl)methacrylamide]—II: Hydrodynamic properties of dilute solutions☆ , 1974 .

[15]  P. Tulkens,et al.  Commentary. Lysosomotropic agents. , 1974, Biochemical pharmacology.

[16]  R. Levy,et al.  The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. , 1975, Cancer research.

[17]  Z Voldrich,et al.  Long-term experience with poly(glycol monomethacrylate) gel in plastic operations of the nose. , 1975, Journal of biomedical materials research.

[18]  H. Ringsdorf.  Structure and properties of pharmacologically active polymers , 1975 .

[19]  J. Kopeček,et al.  New types of synthetic infusion solutions. III. Elimination and retention of poly-[N-(2-hydroxypropyl)methacrylamide] in a test organism. , 1976, Journal of biomedical materials research.

[20]  T. Kitagawa,et al.  Enzyme coupled immunoassay of insulin using a novel coupling reagent. , 1976, Journal of biochemistry.

[21]  V. Saudek,et al.  ENZYMATIC CLEAVAGE OF SIDE CHAINS OF SYNTHETIC WATER-SOLUBLE POLYMERS. , 1976 .

[22]  B. Drewinko,et al.  Comparison of in vitro methods to determine drug-induced cell lethality. , 1976, Cancer research.

[23]  J. Kreuter,et al.  In vitro studies of poly(methyl methacrylate) adjuvants. , 1976, Journal of pharmaceutical sciences.

[24]  G. Birrenbach,et al.  Polymerized micelles and their use as adjuvants in immunology. , 1976, Journal of pharmaceutical sciences.

[25]  J. Labský,et al.  Aminolyses of monomeric and polymeric 4‐nitrophenyl esters of N‐methacryloylamino acids , 1977 .

[26]  J. Kopeček.  Reactive copolymers of N‐(2‐hydroxypropyl)methacrylamide with N‐methacryloylated derivatives of L‐leucine and L‐phenylalanine, 1. Preparation, characterization, and reactions with diamines , 1977 .

[27]  W. Hespe,et al.  Excretion and distribution studies in rats with two forms of 14carbon-labelled polyvinylpyrrolidone with a relatively low mean molecular weight after intravenous administration. , 1977, Arzneimittel-Forschung.

[28]  J. Henkin.  Photolabeling reagent for thiol enzymes. Studies on rabbit muscle creatine kinase. , 1977, The Journal of biological chemistry.

[29]  M. Wilchek,et al.  Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. , 1978, Journal of the National Cancer Institute.

[30]  Y. Ashihara,et al.  Modification of E. coli L-asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum. , 1978, Biochemical and biophysical research communications.

[31]  J. Kopeček,et al.  Synthesis and activity of a polymer which contains insulin covalently bound on a copolymer of N-(2-hydroxypropyl)methacrylamide and N-methacryloyldiglycyl p-nitrophenyl ester , 1978 .

[32]  J Carlsson,et al.  Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. , 1978, The Biochemical journal.

[33]  R. Rees,et al.  Studies on the microcytotoxicity test. II. The uptake of amino acids ([3H]leucine or [75Se]methionine) but not nucleosides ([3H]thymidine or [125I]IUdR) or 51CrO24-provides a direct and quantitative measure of target cell survival in the presence of lymphoid cells. , 1978, Journal of immunological methods.

[34]  Y. Ashihara,et al.  Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum. , 1979, Enzyme.

[35]  H. Ringsdorf,et al.  Antitumor activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis. , 1980, Cancer research.

[36]  K. Ulbrich,et al.  Polymers containing enzymatically degradable bonds V. Hydrophilic polymers degradable by papain. , 1980, Biomaterials.

[37]  L. G. Donaruma,et al.  Anionic polymeric drugs , 1980 .

[38]  I. N. Topchieva.  Biochemical Applications of Poly(Ethylene Glycol) , 1980 .

[39]  J. Weinstein,et al.  Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate. , 1980, Cancer research.

[40]  J. Kopeček,et al.  Immunosuppressive effects of a synthetic polymer poly N-(2-hydroxypropyl)methacrylamide (Duxon). , 1980, Folia biologica.

[41]  D. Neville,et al.  Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[42]  W. Shen,et al.  cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. , 1981, Biochemical and biophysical research communications.

[43]  E. Vanin,et al.  Synthesis and application of cleavable photoactivable heterobifunctional reagents. , 1981, Biochemistry.

[44]  S Davis,et al.  Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. , 1981, Clinical and experimental immunology.

[45]  J. Kopeček,et al.  Polymers containing enzymatically degradable bonds, 2. Poly[N‐(2‐hydroxypropyl)methacrylamide] chains connected by oligopeptide sequences cleavable by chymotrypsin , 1981 .

[46]  K. Ulbrich,et al.  Polymers containing enzymatically degradable bonds, 4. Preliminary experiments in vivo , 1981 .

[47]  H. Ringsdorf,et al.  Effect of molecular size of 125I-labelled poly(vinylpyrrolidone) on its pinocytosis by rat visceral yolk sacs and rat peritoneal macrophages. , 1981, The Biochemical journal.

[48]  T. Kitagawa,et al.  Preparation and Characterization of Hetero-bifunctional Cross-linking Reagents for Protein Modifications , 1981 .

[49]  J. Kopeček,et al.  Polymers containing enzymatically degradable bonds, 1. Chymotrypsin catalyzed hydrolysis of p‐nitroanilides of phenylalanine and tyrosine attached to side‐chains of copolymers of N‐(2‐hydroxypropyl)methacrylamide , 1981 .

[50]  F. Zunino,et al.  Anti‐tumor activity of daunorubicin linked to poly‐L‐aspartic acid , 1982, International journal of cancer.

[51]  M. Poznansky,et al.  Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent. , 1982, Cancer research.

[52]  M. Masquelier,et al.  A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Yee,et al.  The anticancer agent adriamycin can be actively cytotoxic without entering cells. , 1982, Science.

[54]  G. Ashwell,et al.  Carbohydrate-specific receptors of the liver. , 1982, Annual review of biochemistry.

[55]  J. Kopeček.  BIODEGRADATION OF POLYMERS FOR BIOMEDICAL USE , 1982 .

[56]  J. Kopeček,et al.  Degradation of side-chains ofN-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases , 1982, Bioscience reports.

[57]  J. Kopeček,et al.  Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes† , 1983 .

[58]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[59]  S. Pizzo,et al.  A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. , 1983, Analytical biochemistry.

[60]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[61]  J. Kopeček,et al.  Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. , 1983, Biochimica et biophysica acta.

[62]  E. Chiellini,et al.  Polymers in Medicine , 1983 .

[63]  K. Ulbrich,et al.  Synthesis of N-(2-hydroxypropyl)methacrylamide copolymers with antimicrobial activity. , 1983, Biomaterials.

[64]  Jindřich Kopeček,et al.  Polymers containing enzymatically degradable bonds, 8. Degradation of oligopeptide sequences in N‐(2‐hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B , 1983 .

[65]  J. Kopeček,et al.  Soluble synthetic polymers as potential drug carriers , 1984 .

[66]  Y. Takeda,et al.  A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate. , 1984, Journal of medicinal chemistry.

[67]  E. Hersh,et al.  Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. , 1984, The Journal of infectious diseases.

[68]  V. Lenaerts,et al.  Degradation of poly (isobutyl cyanoacrylate) nanoparticles. , 1984, Biomaterials.

[69]  R. Jain,et al.  Plasma pharmacokinetics and interstitial diffusion of macromolecules in a capillary bed. , 1984, The American journal of physiology.

[70]  Toshimitsu Konno,et al.  Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on smancs , 1984 .

[71]  R. W. Baldwin,et al.  Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. , 1984, The Journal of pharmacology and experimental therapeutics.

[72]  S. Davis,et al.  The organ uptake of intravenously administered colloidal particles can be altered using a non‐ionic surfactant (Poloxamer 338) , 1984, FEBS letters.

[73]  J. Kopeček,et al.  Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. , 1984, Biochimica et biophysica acta.

[74]  F. Rypáček,et al.  Soluble synthetic polymers in biological systems , 1984 .

[75]  K. Ulbrich,et al.  Effect of the chemical structure of N- (2- hydroxypropyl) methacrylajnide copolymers on their ability to induce antibody formation in inbred strains of mice , 1984 .

[76]  K. Ingham.  Protein precipitation with polyethylene glycol. , 1984, Methods in enzymology.

[77]  J. Kopeček.  Controlled biodegradability of polymers--a key to drug delivery systems. , 1984, Biomaterials.

[78]  M. Wilchek,et al.  The covalent linking of two nucleotide analogues to antibodies. , 1985, Journal of medicinal chemistry.

[79]  G. Pietersz,et al.  Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. , 1985, Journal of the National Cancer Institute.

[80]  S. Pizzo,et al.  A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. , 1985, The Journal of clinical investigation.

[81]  J. Kopeček,et al.  Preparation of polymer-modified enzymes of prolonged circulation times. Poly[N-(2-hydroxypropyl) methacrylamide]-bound acetylcholinesterase , 1985 .

[82]  K. Ulbrich,et al.  Immunogenicity of N‐(2‐hydroxypropyl) methacrylamide copolymers , 1985 .

[83]  F. Veronese,et al.  Surface modification of proteins activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase , 1985, Applied biochemistry and biotechnology.

[84]  J. Feijen,et al.  OPTIMIZATION OF MACROMOLECULAR PRODRUGS OF THE ANTITUMOR ANTIBIOTIC ADRIAMYCIN , 1985 .

[85]  F. Zunino,et al.  Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug. , 1985, British Journal of Cancer.

[86]  J. Kopeček,et al.  Methods of targeting N‐(2‐hydroxypropyl) methacrylamide copolymers to particular cell types , 1985 .

[87]  K. Ulbrich,et al.  In vivo and in vitro immunogenicity of water-soluble haptenated copolymers for mouse and human lymphocytes , 1985 .

[88]  K H Jones,et al.  An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide. , 1985, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[89]  J. Kopeček,et al.  Controlled Release of Drug Model from N‐(2‐Hydroxypropyl)‐methacrylamide Copolymers , 1985, Annals of the New York Academy of Sciences.

[90]  H. Ryser,et al.  Disulfide spacer between methotrexate and poly(D-lysine). A probe for exploring the reductive process in endocytosis. , 1985, The Journal of biological chemistry.

[91]  B. Říhová,et al.  Biological properties of targetable poly[N-(2-hydroxypropyl)-methacrylamide]-antibody conjugates☆ , 1985 .

[92]  J. Kopeček,et al.  Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. , 1985, Biomaterials.

[93]  J. Kopeček,et al.  Effect of a synthetic poly N-(2-hydroxypropyl)methacrylamide (Duxon) on haemopoiesis and graft-versus-host reaction. , 1986, Folia biologica.

[94]  R. Dwek,et al.  Targeted drug delivery , 1986 .

[95]  J. Sunamoto,et al.  Protein-coated and polysaccharide-coated liposomes as drug carriers. , 1986, Critical reviews in therapeutic drug carrier systems.

[96]  V. L. Alvarez,et al.  Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[97]  S. Davis,et al.  Biodistribution of poly(butyl 2-cyanoacrylate) nanoparticles in rabbits , 1986 .

[98]  J. Koziol,et al.  Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. , 1986, Cancer research.

[99]  S. Howell,et al.  Pharmacologic studies of intra-hepatic artery chemotherapy with degradable starch microspheres. , 1986, Cancer drug delivery.

[100]  J. Kopeček,et al.  Interaction of a Cationic N-(2-hydroxypropyl)methacrylamide Copolymer with Rat Visceral Yolk Sacs Cultured in vitro and Rat Liver in vivo , 1986 .

[101]  B. Říhová,et al.  The Activity of Complement in the Presence of N-(2-hydroxypropyl)methacrylamide Copolymers , 1986 .

[102]  B. Mattiasson,et al.  Efforts to integrate affinity interactions with conventional separation technologies , 1986 .

[103]  M L Yarmush,et al.  Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[104]  L. Huang,et al.  pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. , 1986, Cancer research.

[105]  S. Tsukagoshi,et al.  Synthesis of antitumor‐active conjugates of adriamycin or daunomycin with the copolymer of divinyl ether and maleic anhydride , 1986 .

[106]  B. Ardalan,et al.  Mechanism of action of a new antitumor agent, carbetimer. , 1986, Cancer research.

[107]  T. Ouchi,et al.  Synthesis of acryloyl-type polymer fixing 5-fluorouracil residues through D-glucofuranoses and its antitumor activity , 1986 .

[108]  K. Ulbrich,et al.  Poly(ethylene glycol)s containing enzymatically degradable bonds , 1986 .

[109]  L. Scarlett,et al.  Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. , 1986, Biochimica et biophysica acta.

[110]  J. Kopeček,et al.  Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. , 1987, Journal of biomedical materials research.

[111]  D. D. Hoff,et al.  Experimental Therapy: In Vitro Models , 1987 .

[112]  J. Kopeček,et al.  Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 3. Targeting by incorporation of galactosamine residues. Effect of route of administration , 1987 .

[113]  J. Kopecek,et al.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. , 1987, British Journal of Cancer.

[114]  K. Ulbrich,et al.  Solution properties of drug carriers based on poly[N‐(2‐hydroxypropyl)methacrylamide] containing biodegradable bonds , 1987 .

[115]  W. Laird,et al.  Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[116]  H. Maeda,et al.  Targeting Chemotherapy of Hepatocellular Carcinoma , 1987 .

[117]  K. Ulbrich,et al.  Polymer-bound derivatives of sarcolysin and their antitumour activity against mouse and human leukaemia in vitro , 1987 .

[118]  D. Blakey,et al.  New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. , 1987, Cancer research.

[119]  V. Bocci.  Metabolism of protein anticancer agents. , 1987, Pharmacology & therapeutics.

[120]  M. Smyth,et al.  The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer , 1987, Immunology and cell biology.

[121]  S. Davis,et al.  Targeting of colloidal particles to the bone marrow. , 1987, Life sciences.

[122]  T. Okano,et al.  Surfaces and Blood Compatibility Current Hypotheses , 1987 .

[123]  R. Müller,et al.  The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. , 1987, Life sciences.

[124]  J. Jackson,et al.  An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors. , 1987, Journal of the National Cancer Institute.

[125]  J. Kopeček,et al.  Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers: Pinocytosis by rat visceral yolk sacs and rat intestine cultured in vitro. Effect of molecular weight on uptake and intracellular degradation , 1987 .

[126]  M. Smyth,et al.  Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. , 1987, Cancer research.

[127]  I. McKenzie,et al.  Anti‐tumour activity of aminopterin‐monoclonal antibody conjugates; in vitro and in vivo comparison with methotrexate‐monoclonal antibody conjugates , 1987, Immunology and cell biology.

[128]  F. Muggia,et al.  Clinical Evaluation of Antitumor Therapy , 1987, Developments in Oncology.

[129]  R. Kobayashi,et al.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.

[130]  J. Kopeček,et al.  Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 2. Effect of molecular weight on blood clearance and body distribution in the rat after intravenous administration. Distribution of unfractionated copolymer after intraperitoneal, subcutaneous or oral admin , 1987 .

[131]  J. Kopeček,et al.  Targetable polymeric prodrugs , 1987 .

[132]  J. Kopeček,et al.  Potential of Sugar Residues Attached to N-(2- Hydroxypropyl)methacryl amide Copolymers as Targeting Groups for the Selective Delivery of Drugs , 1987 .

[133]  L. Putten.  Animal Tumor Models for Experimental Therapy , 1987 .

[134]  S. Davis,et al.  Nanoparticles in drug delivery. , 1987, Critical reviews in therapeutic drug carrier systems.

[135]  R. Juliano.  Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions , 1988 .

[136]  L. Denis,et al.  Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. , 1988, The Journal of urology.

[137]  V. Šubr,et al.  Cleavage of oligopeptide side-chains in N-(2-hydroxypropyl)meth-acrylamide copolymers by mixtures of lysosomal enzymes☆ , 1988 .

[138]  C. Alving.  Macrophages as targets for delivery of liposome-encapsulated antimicrobial agents , 1988 .

[139]  M. Smyth,et al.  Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. , 1988, Cancer research.

[140]  K. Kosaka,et al.  A new resuscitation fluid "stabilized hemoglobin" preparation and characteristics. , 1988 .

[141]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[142]  Lisbeth Illum,et al.  Polymers in Controlled Drug Delivery , 1988 .

[143]  S. Becker.  Functions of the human mononuclear phagocyte system (a condensed review) , 1988 .

[144]  G. Pietersz,et al.  Specific in vitro anti‐tumour activity of methotrexate‐monoclonal antibody conjugates prepared using human serum albumin as an intermediary , 1988, Immunology and cell biology.

[145]  G. Storm,et al.  Immunoliposomes in vivo: state of the art , 1988 .

[146]  H. Okada,et al.  Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer. , 1988, Chemical & pharmaceutical bulletin.

[147]  H. Waldmann,et al.  REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H , 1988, The Lancet.

[148]  V. Vetvicka,et al.  Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. , 1988, Clinical immunology and immunopathology.

[149]  H. Okada,et al.  One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. , 1988, The Journal of pharmacology and experimental therapeutics.

[150]  Y. Takeda,et al.  Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates. , 1988, Cancer research.

[151]  J. Sculier,et al.  Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. , 1988, European journal of cancer & clinical oncology.

[152]  J. Kopeček,et al.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. , 1988, British Journal of Cancer.

[153]  K. Yokoyama,et al.  Comparison of efficacy, toxicity and pharmacokinetics of free adriamycin and adriamycin linked to oxidized dextran in rats. , 1989, Chemical & pharmaceutical bulletin.

[154]  J. Kopeček,et al.  Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody conjugates. , 1989, Biochimica et biophysica acta.

[155]  A. Hoshi,et al.  Preparation of Potentially Antitumor-Active Vinyl Polymers Having 5-Fluorouracil Unit as a Component , 1989 .

[156]  F. Zunino,et al.  Poly(carboxylic acid) polymers as carriers for anthracyclines , 1989 .

[157]  K. Ulbrich,et al.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo , 1989 .

[158]  J. H. Lee,et al.  Protein-resistant surfaces prepared by PEO-containing block copolymer surfactants. , 1989, Journal of biomedical materials research.

[159]  R. W. Baldwin,et al.  Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. , 1989, Cancer research.

[160]  L. Scarlett,et al.  Effect of galactose on interaction of N‐(2‐hydroxypropyl)methacrylamide copolymers with hepatoma cells in culture: Preliminary application to an anticancer agent, daunomycin , 1989, Hepatology.

[161]  M. Hashida,et al.  Soluble macromolecular carriers for the delivery of antitumour drugs , 1989 .

[162]  V. H. Lee,et al.  Prodrugs for improved ocular drug delivery , 1989 .

[163]  F. Roerdink,et al.  Drug Carrier Systems , 1989 .

[164]  G. Giammona,et al.  Synthesis of macromolecular prodrugs of procaine, histamine and isoniazid. , 1989, Chemical & pharmaceutical bulletin.

[165]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.

[166]  T. Okano,et al.  Molecular design for missile drug: Synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as intermediate carrier , 1989 .

[167]  J. Conrad,et al.  Controlled sustained delivery of monensin in cattle: The monensin R.D.D.®☆ , 1989 .

[168]  J. Ghrayeb,et al.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[169]  K. Petrak,et al.  Review : Biodegradation of Drug-Modified Polymers in Drug Delivery- A Critical Analysis , 1989 .

[170]  K. Ulbrich,et al.  Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. , 1989, Biomaterials.

[171]  J. Drobník.  Biodegradable soluble macromolecules as drug carriers , 1989 .

[172]  K. Petrak,et al.  Transport of macromolecules across the capillary walls , 1989 .

[173]  K. Ulbrich,et al.  Action of polymeric prodrugs based on N-(2-hydroxypropyl)-methacrylamide copolymers. II. Body distribution and T-cell accumulation of free and polymer-bound [125i]daunomycin , 1989 .

[174]  H. Okada,et al.  Controlled Release of LHRH Agonist, Leuprolide Acetate, from Microcapsules: Serum Drug Level Profiles and Pharmacological Effects in Animals , 1989, The Journal of pharmacy and pharmacology.

[175]  K. Ulbrich,et al.  Action of polymeric prodrugs based on N-(2-hydroxypropyl)meth- acrylamide copolymers. I. Suppression of the antibody response and proliferation of mouse splenocytes in vitro , 1989 .

[176]  H. Maeda,et al.  Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture. , 1989, Anticancer research.

[177]  T. Kubota,et al.  MTT assay with reference to the clinical effect of chemotherapy , 1989, Journal of surgical oncology.

[178]  M. Sela,et al.  Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[179]  R. Baumal,et al.  Sensitivity of multidrug resistant KB-C1 cells to an antibody-dextran-adriamycin conjugate. , 1989, Anticancer research.

[180]  K. Bagshawe.  The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. , 1989, British Journal of Cancer.

[181]  R. Barth,et al.  Boron neutron capture therapy: linkage of a boronated macromolecule to monoclonal antibodies directed against tumor-associated antigens. , 1989, Journal of medicinal chemistry.

[182]  I. Pastan,et al.  Targeted toxin therapy for the treatment of cancer. , 1989, Journal of the National Cancer Institute.

[183]  C J Gomer,et al.  Properties and applications of photodynamic therapy. , 1989, Radiation research.

[184]  T. Kubota,et al.  Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay , 1989, Journal of surgical oncology.

[185]  Y. Takeda,et al.  Preparation and in vitro cytotoxicity of a methotrexate‐anti‐MM46 monoclonal antibody conjugate via an oligopeptide spacer , 1989, International journal of cancer.

[186]  M. Wilchek,et al.  Soluble polymers as carriers of cis-platinum , 1989 .

[187]  J. D. Andrade,et al.  Targetable Photoactivatable Drugs. 1. Synthesis Of Water-Soluble Galactosamine . Containing Polymeric Carriers Of Chlorin E6 And Their Photodynamic Effect On Plc Cells In Vitro , 1989, Other Conferences.

[188]  R. K. Zee-Cheng,et al.  Delivery of anticancer drugs. , 1989, Methods and findings in experimental and clinical pharmacology.

[189]  S. Kaye,et al.  Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. , 1989, Biochemical pharmacology.

[190]  R. Zhuo,et al.  Synthesis and Antitumor Activity of Poly(L-cysteine) Bonded Covalently 5-Fluorouracil , 1990 .

[191]  R. Webb,et al.  Synthesis of 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]butane and 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]but-2-ene, novel heterobifunctional cross-linking reagents. , 1990, Bioconjugate chemistry.

[192]  M. Nakajima,et al.  Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. , 1990, Cancer research.

[193]  Jindrich Kopecˇek.  The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery , 1990 .

[194]  E. Feener,et al.  Cleavage of disulfide bonds in endocytosed macromolecules. A processing not associated with lysosomes or endosomes. , 1990, The Journal of biological chemistry.

[195]  G. Pietersz.  The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer. , 1990, Bioconjugate chemistry.

[196]  S. Davis,et al.  Physiopathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow. , 1990, Critical reviews in therapeutic drug carrier systems.

[197]  A. Abuchowski,et al.  The clinical efficacy of poly(ethylene glycol)-modified proteins , 1990 .

[198]  K. Ulbrich,et al.  Selectivity of Antibody-Targeted Anthracycline Antibiotics on T Lymphocytes , 1990 .

[199]  N. L. Krinick,et al.  Targetable photoactivatable drugs, 2. Synthesis of N‐(2‐hydroxypropyl)methacrylamide copolymeranti‐thy 1.2 antibody‐chlorin e6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro , 1990 .

[200]  H. Weintraub,et al.  Antisense RNA and DNA. , 1990, Scientific American.

[201]  V. Šubr,et al.  Immunogenicity of Protein-N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates in A/J and B10 Mice , 1990 .

[202]  W. L. Joyner,et al.  Microvascular permeability to macromolecules and its dynamic modulation , 1990 .

[203]  P. Couvreur,et al.  Nanoparticles as microcarriers for anticancer drugs , 1990 .

[204]  I. Saiki,et al.  Anti-metastatic and anti-invasive effects of polymeric Arg-Gly-Asp (RGD) peptide, poly(RGD), and its analogues. , 1990, Japanese journal of cancer research : Gann.

[205]  Mcguire Jj,et al.  A human leukemia cell culture system for testing new antifols: differential sensitivity of lymphoid and nonlymphoid cell lines to unconjugated and methotrexate-conjugated polymers of basic amino acids. , 1990 .

[206]  J. Galivan,et al.  Folate analogues. 33. Synthesis of folate and antifolate poly-gamma-glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 hepatoma cells. , 1990, Journal of medicinal chemistry.

[207]  D. O'Shannessy.  Hydrazido-derivatized supports in affinity chromatography. , 1990, Journal of chromatography.

[208]  J. H. Lee,et al.  Surface properties of copolymers of alkyl methacrylates with methoxy (polyethylene oxide) methacrylates and their application as protein-resistant coatings. , 1990, Biomaterials.

[209]  M. Ovadia,et al.  An antimelanoma-barley ribosome inactivating protein conjugate is cytotoxic to melanoma cells in vitro. , 1990, Anticancer research.

[210]  J. Chamberlain.  Is screening for colorectal cancer worthwhile? , 1990, British Journal of Cancer.

[211]  M. Wilchek,et al.  A conjugate of 5-fluorouridine-poly(L-lysine) and an antibody reactive with human colon carcinoma. , 1990, Bioconjugate chemistry.

[212]  K. Ulbrich,et al.  The pharmacokinetics of polymer-bound adriamycin. , 1990, Biochemical pharmacology.

[213]  H. Wada,et al.  Antitumor Enzyme: Polyethylene Glycol–modified Asparaginase , 1990, Annals of the New York Academy of Sciences.

[214]  P. Couvreur,et al.  Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives , 1991 .

[215]  S. Wedge,et al.  Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat. , 1991, British Journal of Cancer.

[216]  K. Ulbrich,et al.  Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. , 1991, Selective cancer therapeutics.

[217]  M. Donbrow,et al.  Microcapsules and Nanoparticles in Medicine and Pharmacy , 1991 .

[218]  T. Tanaka,et al.  Properties of mitomycin C-albumin conjugates in vitro and in vivo. , 1991, Bioconjugate chemistry.

[219]  M C Davies,et al.  Steric stabilization of microspheres with grafted polyethylene oxide reduces phagocytosis by rat Kupffer cells in vitro. , 1991, Biomaterials.

[220]  Robert Huber,et al.  The refined 2.15 A X‐ray crystal structure of human liver cathepsin B: the structural basis for its specificity. , 1991, The EMBO journal.

[221]  N. L. Krinick,et al.  Soluble Polymers as Targetable Drug Carriers , 1991 .

[222]  P. Natali,et al.  Production and characterization of two immunotoxins specific for M5b ANLL leukaemia , 1991, International journal of cancer.

[223]  P. Boon,et al.  Passive immunotherapy of cancer: perspectives and problems , 1991 .

[224]  J. Kopeček.  Targetable Polymeric Anticancer Drugs , 1991, Annals of the New York Academy of Sciences.

[225]  T. Hasan,et al.  Photoimmunotherapy of human ovarian carcinoma cells ex vivo. , 1991, Cancer research.

[226]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. , 1991 .

[227]  T. Okano,et al.  Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. , 1991, Cancer research.

[228]  W. Shen,et al.  Polylysine conjugates of Bowman-Birk protease inhibitor as targeted anti-carcinogenic agents. , 1991, Carcinogenesis.

[229]  K. Ulbrich,et al.  Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N- (2-hydroxypropyl) methacrylamide copolymers , 1991 .

[230]  K. Petrak,et al.  Soluble Polymeric Carriers for Drug Delivery—Part 4: Tissue Autoradiography, and Whole-Body Tissue Distribution in Mice, of N-(2-Hydroxypropyl)Methacrylamide Copolymers Following Intravenous Administration , 1991 .

[231]  D. Goldenberg,et al.  Anthracycline immunoconjugates prepared by a site-specific linkage via an amino-dextran intermediate carrier. , 1991, Cancer research.

[232]  G. Volckaert,et al.  Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule. , 1991, Biochimica et biophysica acta.

[233]  L. Seymour,et al.  Review : Synthetic Polymers with Intrinsic Anticancer Activity , 1991 .

[234]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[235]  J. Feijen,et al.  Association of macromolecular prodrugs consisting of adriamycin bound to poly (L-glutamic acid) , 1991 .

[236]  K. Ulbrich,et al.  N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. , 1991, British Journal of Cancer.

[237]  H. Tanaka,et al.  Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. , 1991, Cancer research.

[238]  M. Maeda,et al.  Signal‐Sensitive Release of Contents from Liposomes Bearing Surface‐Grafted Polyelectrolyte Chains a , 1991, Annals of the New York Academy of Sciences.

[239]  R. Collins,et al.  Phase I immunotoxin trial in patients with B-cell lymphoma. , 1991, Cancer research.

[240]  S. Suzuki,et al.  Synthesis and antitumor activity of α-1,4-polygalactosamine and N-acetyl-α-1,4-polygalactosamine immobilized 5-fluorouracils through hexamethylene spacer groups via urea, urea bonds , 1991 .

[241]  R. Youle,et al.  Comparison of protein synthesis inhibition kinetics and cell killing induced by immunotoxins. , 1991, The Journal of biological chemistry.

[242]  Wawrzynczak Ej.  Systemic immunotoxin therapy of cancer: advances and prospects. , 1991 .

[243]  I. Pastan,et al.  Recombinant toxins for cancer treatment. , 1991, Science.

[244]  N. L. Krinick,et al.  Targetable photoactivatable polymeric drugs , 1991 .

[245]  F. Maxfield,et al.  Internalization and Sorting of Macromolecules: Endocytosis , 1991 .

[246]  S. Shah,et al.  Immunoconjugates containing novel maytansinoids: promising anticancer drugs. , 1992, Cancer research.

[247]  I. Pastan,et al.  Targeting growth factor receptors with fusion toxins. , 1992, International journal of immunopharmacology.

[248]  H. Dvorak,et al.  Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. , 1992, Cancer research.

[249]  J. Kopeček,et al.  Photoregulated association of N-(2-hydroxypropyl)methacrylamide copolymers with azobenzene-containing side chains , 1992 .

[250]  S. Zalipsky,et al.  Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides , 1992 .

[251]  K. Petrak,et al.  Soluble Polymeric Carriers for Drug Delivery: Part 5: Solution Properties and Biodistribution Behaviour of N-(2-Hydroxypropyl)Methacrylamide-co-N-(2-[4-Hydroxyphenyl]Ethyl) Acrylamide Copolymer Substituted with Cholesterol , 1992 .

[252]  T. Allen,et al.  Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. , 1992, Cancer research.

[253]  G. Molema,et al.  Drug targeting systems for antiviral agents: options and limitations. , 1992, Antiviral research.

[254]  M. Brinkley.  A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents. , 1992, Bioconjugate chemistry.

[255]  C Delgado,et al.  The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.

[256]  M. Hashida,et al.  Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. , 1992, Bioconjugate chemistry.

[257]  R. Duncan,et al.  Drug-polymer conjugates: potential for improved chemotherapy. , 1992, Anti-cancer drugs.

[258]  M. Siegel,et al.  Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins .beta.1Br, .gamma.1Br, .alpha.2I, .alpha.3I, .beta.1I, .gamma.1I, and .delta.1I , 1992 .

[259]  H. Maeda,et al.  Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.

[260]  Mu‐Hsien Yu,et al.  Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma , 1992, International journal of cancer.

[261]  K. Ulbrich,et al.  Preclinical evaluation of polymer-bound doxorubicin , 1992 .

[262]  Dale D. Myers.  The Navaho cruise missile—A burst of technology , 1992 .

[263]  T. Kubota,et al.  Targeting cancer chemotherapy using a monoclonal antibody (NCC‐LU‐243) conjugated with mitomycin C , 1992, Journal of surgical oncology.

[264]  J. M. Harris,et al.  Poly(Ethylene Glycol) Chemistry Biotechnical and Biomedical Applications , 1992 .

[265]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[266]  W. E. Ford,et al.  Antibody‐Targeted Photolysis: In Vitro Immunological, Photophysical, and Cytotoxic Properties of Monoclonal Antibody‐Dextran‐Sn(IV) Chlorin e6 Immunoconjugates , 1992, Biotechnology progress.

[267]  S L Morrison,et al.  Genetically engineered antibodies: progress and prospects. , 1992, Critical reviews in immunology.

[268]  J. Keana,et al.  Molecular amplifiers: synthesis and functionalization of a poly(aminopropyl)dextran bearing a uniquely reactive terminus for univalent attachment to biomolecules. , 1992, Bioconjugate chemistry.

[269]  I. Pastan,et al.  Recombinant toxins as novel therapeutic agents. , 1992, Annual review of biochemistry.

[270]  T. Dougherty,et al.  HOW DOES PHOTODYNAMIC THERAPY WORK? , 1992, Photochemistry and photobiology.

[271]  B. Morland,et al.  Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules. , 1992, British Journal of Cancer.

[272]  K. Ulbrich,et al.  Antibody-targeted cyclosporin A , 1992 .

[273]  F. Askari,et al.  Targeted delivery of antisense oligonucleotides by molecular conjugates , 1992, Somatic cell and molecular genetics.

[274]  L. Seymour.  Passive tumor targeting of soluble macromolecules and drug conjugates. , 1992, Critical reviews in therapeutic drug carrier systems.

[275]  B. Allison,et al.  Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems , 1992 .

[276]  K. Tomoo,et al.  Crystallization and preliminary X-ray study of the cathepsin B complexed with CA074, a selective inhibitor. , 1992, Journal of molecular biology.

[277]  J. Kopeček,et al.  Synthesis and photoproperties of a substituted zinc(II) phthalocyanine-N-(2-hydroxypropyl)methacrylamide copolymer conjugate , 1993 .

[278]  K. Ulbrich,et al.  Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma. , 1993, Journal of drug targeting.

[279]  N. L. Krinick,et al.  Targetable photoactivalable drugs. 3. In vitro efficacy of polymer bound chlorin e6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies , 1993 .

[280]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[281]  Y. Ikada,et al.  Body distribution profile of polysaccharides after intravenous administration , 1993 .

[282]  Kazuya Okamoto,et al.  composition-dependent in vivo antitumor activity of adriamycin-conjugated polymeric micelle against murine colon adenocarcinoma 26 , 1993 .

[283]  P. Trail,et al.  (6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin. , 1993, Bioconjugate chemistry.

[284]  N. Petrelli,et al.  Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). , 1993, Cancer research.

[285]  M. Gospodarowicz,et al.  Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[286]  Y. Tsukada,et al.  Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro , 2022 .

[287]  Y. Ito,et al.  Trypsin modification by vinyl polymers with variable solubilities in response to external signals. , 1993, Bioconjugate chemistry.

[288]  T. Nagai,et al.  Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate. , 1993, Biological & pharmaceutical bulletin.

[289]  A. Schally,et al.  Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[290]  I Horikoshi,et al.  Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery. , 1993, Cancer research.

[291]  E. Nabel,et al.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[292]  T. Okano,et al.  Temperature-responsive bioconjugates. 1. Synthesis of temperature-responsive oligomers with reactive end groups and their coupling to biomolecules. , 1993, Bioconjugate chemistry.

[293]  D. Neville,et al.  Anti-T cell immunotoxins: a look at post-endocytotic receptor-mediated routing , 1993 .

[294]  I. Pastan,et al.  Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. , 1993, Cancer research.

[295]  D. Anderson,et al.  Enhanced in vitro tumor cell retention and internalization of antibody derivatized with synthetic peptides. , 1993, Bioconjugate chemistry.

[296]  R. Wallace,et al.  Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. , 1993, Cancer research.

[297]  J. Kopeček,et al.  Enzymatic activity of chymotrypsin and its poly(ethylene glycol) conjugates toward low and high molecular weight substrates. , 1993, Bioconjugate chemistry.

[298]  Y. Cheng,et al.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical? , 1993, Science.

[299]  Govind Rao,et al.  Comparison of Trypan Blue Dye Exclusion and Fluorometric Assays for Mammalian Cell Viability Determinations , 1993, Biotechnology progress.

[300]  D. Kerr,et al.  Generation of cytotoxic agents by targeted enzymes. , 1993, Bioconjugate chemistry.

[301]  J. Feijen,et al.  BIOLOGICAL PROPERTIES OF ADRIAMYCIN BOUND TO BIODEGRADABLE POLYMERIC CARRIERS , 1993 .

[302]  T. Okano,et al.  Temperature-responsive bioconjugates. 2. Molecular design for temperature-modulated bioseparations. , 1993, Bioconjugate chemistry.

[303]  W. F. Anderson.  Gene therapy for cancer. , 1994, Human gene therapy.

[304]  J. Kopeček,et al.  Enzymatic Degradation of Poly(ethylene glycol) Modified Dextrans , 1994 .

[305]  N. L. Krinick,et al.  A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. , 1994, Journal of biomaterials science. Polymer edition.